Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function

John M. Seubert, Christopher J. Sinal, Joan Graves, Laura M. Degraff, J. Alyce Bradbury, Craig R. Lee, Kerry Goralski, Michelle A. Carey, Ayala Luria, John W. Newman, Bruce D. Hammock, John R. Falck, Holly Roberts, Howard A. Rockman, Elizabeth Murphy, Darryl C. Zeldin

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Ephx2, sEH). To examine the functional role of sEH in the heart, mice with targeted disruption of the Ephx2 gene were studied. Hearts from sEH null mice have undetectable levels of sEH mRNA and protein and cannot convert EETs to DHETs. sEH null mice have normal heart anatomy and basal contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocyte cell culture media compared with wild type (WT). sEH null hearts have improved recovery of left ventricular developed pressure (LVDP) and less infarction compared with WT hearts after 20 minutes ischemia. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (10 to 100 nmol/L) before ischemia abolishes this cardioprotective phenotype. Inhibitor studies demonstrate that perfusion with phosphatidylinositol-3 kinase (PI3K) inhibitors wortmannin (200 nmol/L) or LY294002 (5 μmol/L), the ATP-sensitive K channel (KATP) inhibitor glibenclamide (1 μmol/L), the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (100 to 200 μmol/L), or the Ca-sensitive K channel (KCa) inhibitor paxilline (10 μmol/L) abolishes the cardioprotection in sEH null hearts. Consistent with increased activation of the PI3K cascade, sEH null mice exhibit increased cardiac expression of glycogen synthase kinase-3β (GSK-3β) phospho-protein after ischemia. Together, these data suggest that targeted disruption of sEH increases the availability of cardioprotective EETs that work by activating PI3K signaling pathways and K channels.

Original languageEnglish (US)
Pages (from-to)442-450
Number of pages9
JournalCirculation Research
Volume99
Issue number4
DOIs
StatePublished - Aug 2006

Fingerprint

Epoxide Hydrolases
Phosphatidylinositol 3-Kinase
Ischemia
Perfusion
Glycogen Synthase Kinase 3
KATP Channels
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Acids
Glyburide
Epoxy Compounds
Ventricular Pressure
Plasma Cells
Cardiac Myocytes
Arachidonic Acid
Cytochrome P-450 Enzyme System
Infarction
Culture Media
Anatomy
Proteins
Fatty Acids

Keywords

  • Arachidonic acid
  • Cytochrome P450
  • Eicosanoid
  • Ischemia/reperfusion

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Seubert, J. M., Sinal, C. J., Graves, J., Degraff, L. M., Bradbury, J. A., Lee, C. R., ... Zeldin, D. C. (2006). Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circulation Research, 99(4), 442-450. https://doi.org/10.1161/01.RES.0000237390.92932.37

Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. / Seubert, John M.; Sinal, Christopher J.; Graves, Joan; Degraff, Laura M.; Bradbury, J. Alyce; Lee, Craig R.; Goralski, Kerry; Carey, Michelle A.; Luria, Ayala; Newman, John W.; Hammock, Bruce D.; Falck, John R.; Roberts, Holly; Rockman, Howard A.; Murphy, Elizabeth; Zeldin, Darryl C.

In: Circulation Research, Vol. 99, No. 4, 08.2006, p. 442-450.

Research output: Contribution to journalArticle

Seubert, JM, Sinal, CJ, Graves, J, Degraff, LM, Bradbury, JA, Lee, CR, Goralski, K, Carey, MA, Luria, A, Newman, JW, Hammock, BD, Falck, JR, Roberts, H, Rockman, HA, Murphy, E & Zeldin, DC 2006, 'Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function', Circulation Research, vol. 99, no. 4, pp. 442-450. https://doi.org/10.1161/01.RES.0000237390.92932.37
Seubert, John M. ; Sinal, Christopher J. ; Graves, Joan ; Degraff, Laura M. ; Bradbury, J. Alyce ; Lee, Craig R. ; Goralski, Kerry ; Carey, Michelle A. ; Luria, Ayala ; Newman, John W. ; Hammock, Bruce D. ; Falck, John R. ; Roberts, Holly ; Rockman, Howard A. ; Murphy, Elizabeth ; Zeldin, Darryl C. / Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. In: Circulation Research. 2006 ; Vol. 99, No. 4. pp. 442-450.
@article{8cf09c043c094d7c93e1da997da62b70,
title = "Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function",
abstract = "Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Ephx2, sEH). To examine the functional role of sEH in the heart, mice with targeted disruption of the Ephx2 gene were studied. Hearts from sEH null mice have undetectable levels of sEH mRNA and protein and cannot convert EETs to DHETs. sEH null mice have normal heart anatomy and basal contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocyte cell culture media compared with wild type (WT). sEH null hearts have improved recovery of left ventricular developed pressure (LVDP) and less infarction compared with WT hearts after 20 minutes ischemia. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (10 to 100 nmol/L) before ischemia abolishes this cardioprotective phenotype. Inhibitor studies demonstrate that perfusion with phosphatidylinositol-3 kinase (PI3K) inhibitors wortmannin (200 nmol/L) or LY294002 (5 μmol/L), the ATP-sensitive K channel (KATP) inhibitor glibenclamide (1 μmol/L), the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (100 to 200 μmol/L), or the Ca-sensitive K channel (KCa) inhibitor paxilline (10 μmol/L) abolishes the cardioprotection in sEH null hearts. Consistent with increased activation of the PI3K cascade, sEH null mice exhibit increased cardiac expression of glycogen synthase kinase-3β (GSK-3β) phospho-protein after ischemia. Together, these data suggest that targeted disruption of sEH increases the availability of cardioprotective EETs that work by activating PI3K signaling pathways and K channels.",
keywords = "Arachidonic acid, Cytochrome P450, Eicosanoid, Ischemia/reperfusion",
author = "Seubert, {John M.} and Sinal, {Christopher J.} and Joan Graves and Degraff, {Laura M.} and Bradbury, {J. Alyce} and Lee, {Craig R.} and Kerry Goralski and Carey, {Michelle A.} and Ayala Luria and Newman, {John W.} and Hammock, {Bruce D.} and Falck, {John R.} and Holly Roberts and Rockman, {Howard A.} and Elizabeth Murphy and Zeldin, {Darryl C.}",
year = "2006",
month = "8",
doi = "10.1161/01.RES.0000237390.92932.37",
language = "English (US)",
volume = "99",
pages = "442--450",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function

AU - Seubert, John M.

AU - Sinal, Christopher J.

AU - Graves, Joan

AU - Degraff, Laura M.

AU - Bradbury, J. Alyce

AU - Lee, Craig R.

AU - Goralski, Kerry

AU - Carey, Michelle A.

AU - Luria, Ayala

AU - Newman, John W.

AU - Hammock, Bruce D.

AU - Falck, John R.

AU - Roberts, Holly

AU - Rockman, Howard A.

AU - Murphy, Elizabeth

AU - Zeldin, Darryl C.

PY - 2006/8

Y1 - 2006/8

N2 - Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Ephx2, sEH). To examine the functional role of sEH in the heart, mice with targeted disruption of the Ephx2 gene were studied. Hearts from sEH null mice have undetectable levels of sEH mRNA and protein and cannot convert EETs to DHETs. sEH null mice have normal heart anatomy and basal contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocyte cell culture media compared with wild type (WT). sEH null hearts have improved recovery of left ventricular developed pressure (LVDP) and less infarction compared with WT hearts after 20 minutes ischemia. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (10 to 100 nmol/L) before ischemia abolishes this cardioprotective phenotype. Inhibitor studies demonstrate that perfusion with phosphatidylinositol-3 kinase (PI3K) inhibitors wortmannin (200 nmol/L) or LY294002 (5 μmol/L), the ATP-sensitive K channel (KATP) inhibitor glibenclamide (1 μmol/L), the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (100 to 200 μmol/L), or the Ca-sensitive K channel (KCa) inhibitor paxilline (10 μmol/L) abolishes the cardioprotection in sEH null hearts. Consistent with increased activation of the PI3K cascade, sEH null mice exhibit increased cardiac expression of glycogen synthase kinase-3β (GSK-3β) phospho-protein after ischemia. Together, these data suggest that targeted disruption of sEH increases the availability of cardioprotective EETs that work by activating PI3K signaling pathways and K channels.

AB - Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs) which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Ephx2, sEH). To examine the functional role of sEH in the heart, mice with targeted disruption of the Ephx2 gene were studied. Hearts from sEH null mice have undetectable levels of sEH mRNA and protein and cannot convert EETs to DHETs. sEH null mice have normal heart anatomy and basal contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocyte cell culture media compared with wild type (WT). sEH null hearts have improved recovery of left ventricular developed pressure (LVDP) and less infarction compared with WT hearts after 20 minutes ischemia. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (10 to 100 nmol/L) before ischemia abolishes this cardioprotective phenotype. Inhibitor studies demonstrate that perfusion with phosphatidylinositol-3 kinase (PI3K) inhibitors wortmannin (200 nmol/L) or LY294002 (5 μmol/L), the ATP-sensitive K channel (KATP) inhibitor glibenclamide (1 μmol/L), the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (100 to 200 μmol/L), or the Ca-sensitive K channel (KCa) inhibitor paxilline (10 μmol/L) abolishes the cardioprotection in sEH null hearts. Consistent with increased activation of the PI3K cascade, sEH null mice exhibit increased cardiac expression of glycogen synthase kinase-3β (GSK-3β) phospho-protein after ischemia. Together, these data suggest that targeted disruption of sEH increases the availability of cardioprotective EETs that work by activating PI3K signaling pathways and K channels.

KW - Arachidonic acid

KW - Cytochrome P450

KW - Eicosanoid

KW - Ischemia/reperfusion

UR - http://www.scopus.com/inward/record.url?scp=33747422507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747422507&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000237390.92932.37

DO - 10.1161/01.RES.0000237390.92932.37

M3 - Article

VL - 99

SP - 442

EP - 450

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 4

ER -